NCT01911221View on ClinicalTrials.gov

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

PHASE3CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Prevention of the Meningococcal Disease
Interventions
BIOLOGICAL

rMenB+OMV NZ

Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain

Trial Locations (1)

35037

Novartis site, Marburg

Sponsors

Lead Sponsor

Novartis Vaccines

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Novartis Vaccines

INDUSTRY

NCT01911221 - A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. | Biotech Hunter | Biotech Hunter